Thematic evaluation
Back to company overview

Boston Scientific Corp. (BSX)

September 06, 2024

Compared to: Stryker Corp. (SYK) | Medtronic Plc (MDT) | Health Care Select Sector SPDR Fund (XLV)

Our reasoning

Boston Scientific's current valuation appears slightly overvalued due to its above-average valuation multiples compared to historical averages and industry peers. However, the company's strong financial performance, market leadership, and robust growth prospects partially justify this premium valuation. The potential for successful integration of recent acquisitions and continued innovation could support the current valuation, but risks such as high debt levels and regulatory challenges warrant caution.

Key takeaways
  • Boston Scientific is a leading global medical device company with a strong track record of revenue growth and profitability.
  • The company's recent acquisitions have contributed to its growth, but have also increased its debt levels.
  • The company's liquidity position is strong, but its debt-to-equity ratio is relatively high, indicating a significant level of financial leverage.
  • The company's cash flow generation is robust, and its free cash flow margin is significantly above the industry average.
  • The company's future outlook is positive, with continued revenue growth, expanding profitability, and strong financial flexibility expected.
  • The company's valuation is currently above the industry average, reflecting its strong financial performance, growth prospects, and market leadership.
  • The company's price performance has been strong, but its higher volatility suggests a slightly higher risk profile.
  • Boston Scientific's overall investment characteristics are attractive, with strong financial performance, growth potential, and a solid track record of strategic execution. However, investors should be aware of the company's high debt levels and the risks associated with its recent acquisitions.
Overvalued
Ask a question about Boston Scientific Corp. (BSX)
Evaluation summary

  1. Company Overview:

    • Boston Scientific Corp. (BSX) is a global medical device company that develops, manufactures, and markets a diverse range of products used in interventional medical procedures. The company operates through two segments: MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation, while the Cardiovascular segment consists of Cardiology and Peripheral Interventions. BSX's primary competitors include Abbott Laboratories, Medtronic plc, and other medical device companies.
    • BSX's product portfolio includes devices for cardiology, endoscopy, urology, and neuromodulation procedures. The company's revenue is generated primarily through direct sales to hospitals, clinics, and physicians, as well as through independent distributors and dealers in international markets.
    • BSX targets a broad range of customers, including hospitals, clinics, physicians, and patients. The company's products are used in a variety of medical procedures, including coronary artery disease, heart failure, atrial fibrillation, peripheral artery disease, and other conditions.
    • We are using the Health Care Select Sector SPDR Fund (XLV) as a benchmark for BSX's price performance and Stryker Corp. (SYK) and Medtronic Plc (MDT) as industry peers for comparative analysis.

  2. Financial Performance:

    • BSX has demonstrated strong revenue growth in recent quarters, driven by the rapid adoption of the FARAPULSE PFA System and strong performance across other business units and regions. The company's revenue growth is expected to continue, driven by its robust product pipeline and global commercial capabilities.
    • BSX's profitability is strong, with a high return on equity and a growing EBITDA margin. The company's profitability is significantly above the industry average, indicating superior performance relative to peers.
    • BSX's profitability is trending upwards, indicating improving performance. The company's gross profit margin has been impacted by inflation, supply chain challenges, and inventory charges, but is expected to improve in the second half of the year.
    • BSX's return on assets (ROA), return on equity (ROE), and return on invested capital (ROIC) are all above the industry average, indicating efficient asset utilization and strong profitability.
    • Compared to its peers, BSX has consistently outperformed SYK and MDT in terms of revenue growth, profitability, and return on equity.

  3. Operational Efficiency:

    • BSX's balance sheet is strong, with a significant amount of cash on hand and a healthy working capital position. The company's liquidity position is trending upwards, indicating improving liquidity.
    • BSX's working capital management is effective, with a current ratio greater than 1 and a strong cash flow from operations. The company's working capital efficiency is slightly weaker than the industry average, suggesting a slightly less conservative approach to liquidity management.
    • BSX's cash flows from operations are increasing, driven by strong earnings growth and effective working capital management. The company's capital expenditures are decreasing, potentially indicating a slowdown in investment or a shift in the company's growth strategy.
    • BSX's asset quality is good, with a low level of goodwill and intangible assets. The company's asset utilization efficiency is improving, as evidenced by the increasing return on assets.
    • BSX's free cash flow margin is positive, indicating that the company is generating cash flow in excess of its capital expenditures. The company's free cash flow is expected to continue to grow, driven by its strong earnings growth and effective working capital management.
    • BSX's capital expenditures are decreasing, potentially indicating a slowdown in investment or a shift in the company's growth strategy.
    • BSX does not currently pay dividends, but its strong cash flow generation and financial flexibility suggest that dividend payments could be considered in the future.
    • Compared to its peers, BSX has a stronger liquidity position, higher free cash flow margin, and lower capital expenditures.
    • BSX's short-term and long-term liquidity ratios are strong, indicating a healthy financial position.
    • BSX's debt-to-equity and leverage ratios are relatively high, indicating a significant level of financial leverage. However, the company's debt-to-equity ratio is below the industry average, suggesting a more conservative capital structure compared to peers.

  4. Growth Opportunities:

    • BSX has a robust product pipeline and is actively pursuing market expansion opportunities through strategic acquisitions, geographic expansion, and product innovation.
    • BSX has recently completed acquisitions of Apollo Endosurgery, Acotec Scientific Holdings, and Relievant Medsystems to expand its product portfolio and capabilities. The company has also announced definitive agreements to acquire Axonics, Inc. and Silk Road Medical, Inc. to further strengthen its urology and peripheral interventions businesses.
    • BSX is investing heavily in R&D to develop new products and technologies. The company's R&D pipeline includes a number of promising products that could drive future growth.
    • BSX is expanding its geographic reach, particularly in emerging markets. The company's global commercial capabilities are expected to drive future growth.
    • BSX's strategic focus areas include expanding its cardiovascular portfolio, strengthening its urology and peripheral interventions franchises, and investing in clinical evidence generation to maintain its leadership position in the PFA market.
    • BSX has a strong track record of executing on its strategic plans. The company's recent acquisitions and product launches have been successful, and its financial performance has been strong.
    • BSX's capital allocation strategy is focused on investing in growth opportunities, including acquisitions, R&D, and geographic expansion. The company's capital allocation strategy is aligned with its long-term growth objectives.

  5. Risks and Threats:

    • BSX faces a number of risks, including competition, regulatory changes, economic uncertainty, and legal challenges.
    • BSX's primary competitors include Abbott Laboratories, Medtronic plc, and other medical device companies. The medical device industry is highly competitive, with rapid technological change and innovation.
    • BSX faces regulatory compliance challenges and heightened global enforcement in the medical device industry. The company is subject to a number of regulations, including those related to product safety, efficacy, and labeling.
    • BSX is exposed to challenging economic conditions, including inflation, supply chain disruptions, and currency fluctuations. The company's international sales expose it to geopolitical dynamics.
    • BSX is facing ongoing patent litigation proceedings and product liability claims related to transvaginal surgical mesh products. The company is also subject to governmental investigations and qui tam matters, including alleged anti-competitive behavior and FCPA violations.

  6. Valuation Analysis:

    • BSX's valuation is currently above the industry average, based on metrics such as price-to-earnings (P/E) ratio, enterprise value-to-EBITDA (EV/EBITDA), and price-to-sales (P/S) ratio.
    • Compared to its peers, BSX is trading at a premium valuation, reflecting its strong financial performance, growth prospects, and market leadership.
    • Potential catalysts for BSX's valuation include continued revenue growth, expanding profitability, and successful integration of recent acquisitions.

  7. Price Performance:

    • BSX's stock price has consistently outperformed the Health Care Select Sector SPDR Fund (XLV) over various time periods, including year-to-date, one-week, one-month, three-month, six-month, one-year, two-year, and three-year periods.
    • BSX has exhibited higher annualized volatility than XLV, indicating that BSX is more sensitive to market fluctuations. This is further supported by the drawdown figures, where BSX has experienced a larger maximum drawdown than XLV.
    • BSX's beta values indicate that it is less volatile than the overall market but still more sensitive to market movements than XLV.
    • Compared to its peers, BSX has consistently outperformed SYK and MDT in terms of price performance.
    • BSX's price performance has been strong, but its higher volatility suggests a slightly higher risk profile.

  8. Future Outlook:

    • BSX's management has provided positive guidance for the remainder of 2024, with continued revenue growth, expanding profitability, and strong financial flexibility expected.
    • Analyst estimates for BSX's future performance are generally positive, with consensus expectations for continued revenue growth and earnings per share (EPS) growth.
    • BSX's future outlook is positive, with continued revenue growth, expanding profitability, and strong financial flexibility expected. The company's robust product pipeline, global commercial capabilities, and focus on operational optimization through restructuring provide opportunities for continued growth.

  9. Summary:

    • BSX is a leading global medical device company with a strong track record of revenue growth and profitability. The company's recent acquisitions have contributed to its growth, but have also increased its debt levels.
    • BSX's liquidity position is strong, but its debt-to-equity ratio is relatively high, indicating a significant level of financial leverage.
    • BSX's cash flow generation is robust, and its free cash flow margin is significantly above the industry average.
    • BSX's future outlook is positive, with continued revenue growth, expanding profitability, and strong financial flexibility expected. The company's robust product pipeline, global commercial capabilities, and focus on operational optimization through restructuring provide opportunities for continued growth.
    • BSX's valuation is currently above the industry average, reflecting its strong financial performance, growth prospects, and market leadership.
    • BSX's price performance has been strong, but its higher volatility suggests a slightly higher risk profile.
    • BSX's overall investment characteristics are attractive, with strong financial performance, growth potential, and a solid track record of strategic execution. However, investors should be aware of the company's high debt levels and the risks associated with its recent acquisitions.
Peer fundamentals 
Fundamentals
Insights
  • Boston Scientific is a leading global medical device company with a strong track record of revenue growth and profitability.
  • The company's recent acquisitions have contributed to its growth, but have also increased its debt levels.
  • The company's liquidity position is strong, but its debt-to-equity ratio is relatively high, indicating a significant level of financial leverage.
  • The company's cash flow generation is robust, and its free cash flow margin is significantly above the industry average.
  • The company's future outlook is positive, with continued revenue growth, expanding profitability, and strong financial flexibility expected.
Analysis
  • Revenue - Boston Scientific's revenue growth is strong and appears sustainable, driven by its diverse product portfolio and recent acquisitions. - The company's revenue growth is driven by the rapid adoption of the FARAPULSE PFA System, as well as strong performance across other business units and regions. - The company's revenue growth is expected to continue, driven by its robust product pipeline and global commercial capabilities.
    • Profitability
      • The company's profitability is strong, with a high return on equity and a growing EBITDA margin.
      • The company's profitability is significantly above the industry average, indicating superior performance relative to peers.
      • The company's profitability is trending upwards, indicating improving performance.
    • Liquidity
      • The company's liquidity position is strong, with a current ratio greater than 1 and a significant amount of cash on hand.
      • The company's liquidity position is slightly weaker than the industry average, suggesting a slightly less conservative approach to liquidity management.
      • The company's liquidity position is trending upwards, indicating improving liquidity.
    • Solvency
      • The company's long-term solvency is strong, with a high cash flow to total debt ratio and a growing EBITDA margin.
      • The company's debt-to-equity ratio is relatively high, indicating a significant level of financial leverage.
      • The company's debt-to-equity ratio is below the industry average, suggesting a more conservative capital structure compared to peers.
    • Operational Efficiency
      • The company's asset utilization efficiency is improving, as evidenced by the increasing return on assets.
      • The company is effectively managing its expenses, leading to expanding operating margins.
      • The company's free cash flow margin is positive, indicating that the company is generating cash flow in excess of its capital expenditures.
    • Cash Flow Analysis
      • The company's cash flows from operations are increasing, driven by strong earnings growth and effective working capital management.
      • The company's capital expenditures are decreasing, potentially indicating a slowdown in investment or a shift in the company's growth strategy.
      • The company's debt financing is expected to continue, as it supports its growth initiatives and acquisitions.
    • Risk Factors
      • The increasing level of debt could pose a risk if the company's earnings growth slows or if interest rates rise.
      • The company's recent acquisitions have contributed to the increase in debt and other current liabilities.
      • The company's recent acquisitions have contributed to the increase in debt financing.
    • Future Outlook
      • The company's balance sheet is expected to continue to grow, driven by its strategic initiatives and strong earnings.
      • The company's cash flows from operations are expected to continue to grow, driven by its strong earnings growth and effective working capital management.
      • The company's revenue growth is expected to continue, driven by its robust product pipeline and global commercial capabilities.
      • The company's profitability is expected to improve, driven by margin expansion and operational optimization.
      • The company's financial flexibility is expected to remain strong, supported by its robust cash flow generation and liquidity position.
Most recent earnings report
Financial statements 
All public filings
Comparative Analysis
Benchmarks (as of 2024-09-04)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison: Boston Scientific Corp. (BSX) has consistently outperformed the Health Care Select Sector SPDR Fund (XLV) over various time periods, including year-to-date, one-week, one-month, three-month, six-month, one-year, two-year, and three-year periods. This suggests that BSX has experienced a stronger growth trajectory compared to the broader healthcare sector.
  • Risk and Return Analysis: BSX has provided higher annualized returns than XLV over the past three years. However, BSX has also exhibited higher annualized volatility than XLV, indicating that BSX is more sensitive to market fluctuations. This is further supported by the drawdown figures, where BSX has experienced a larger maximum drawdown than XLV. This suggests that BSX carries a slightly higher risk profile compared to XLV.
  • Risk-Adjusted Performance: While BSX has provided higher returns, XLV has offered a better risk-adjusted return, as indicated by its consistently higher Sharpe Ratio. This suggests that XLV has been more efficient in generating returns relative to its risk. BSX's beta values indicate that it is less volatile than the overall market but still more sensitive to market movements than XLV. This suggests that BSX carries a slightly higher risk profile compared to XLV.
  • Overall Assessment: Boston Scientific Corp. (BSX) has demonstrated strong growth and outperformance compared to the Health Care Select Sector SPDR Fund (XLV). However, BSX's higher volatility and larger drawdowns suggest a slightly higher risk profile. While BSX has provided higher returns, XLV has offered a better risk-adjusted return. Investors seeking higher potential returns may consider BSX, but they should be aware of its higher risk profile. Investors seeking a more stable and risk-averse investment may prefer XLV.
Peers Price History(as of 2024-09-04)
Stryker Corp. (SYK)Medtronic Plc (MDT)
  • Performance Comparison: Boston Scientific Corp. (BSX) has consistently outperformed its peers, Stryker Corp. (SYK) and Medtronic Plc (MDT), across all historical periods analyzed. This outperformance is particularly notable in the longer-term periods, with BSX delivering significantly higher returns over the past 2 and 3 years.
  • Risk and Return Analysis: While BSX has delivered higher returns than its peers, it has also exhibited lower annualized volatility. This suggests that BSX has been able to generate strong returns with a lower level of risk. Furthermore, BSX has experienced the smallest maximum drawdown among the three companies, further reinforcing its lower risk profile.
  • Risk-Adjusted Performance: BSX's Sharpe ratio has consistently been higher than SYK's and MDT's, indicating that it has offered a better risk-adjusted return. This is further supported by BSX's lower beta, which suggests that it is less sensitive to market movements and therefore carries a lower risk.
  • Overall Assessment: Boston Scientific Corp. (BSX) appears to be a strong performer in the medical device industry, consistently outperforming its peers while exhibiting a lower risk profile. Its lower volatility, smaller drawdowns, and higher Sharpe ratio suggest that BSX is a more attractive investment option for investors seeking a balance of risk and return. However, it is important to note that the recent trends in volatility and drawdowns suggest that BSX may be becoming more volatile, which could impact its future performance.
Peers Fundamentals(as of 2024-06-30)
Stryker Corp. (SYK)Medtronic Plc (MDT)

  1. Market Position and Size:

    • Boston Scientific Corp. (BSX) is a mid-sized player in the medical device industry, with a market capitalization that falls between its larger peers, Stryker Corp. (SYK) and Medtronic Plc (MDT).
    • While BSX's market cap is closer to SYK, its revenue and profitability are significantly lower, suggesting that it may be less efficient at generating returns than its larger peers.

  2. Profitability and Efficiency:

    • BSX exhibits a strong Gross Profit Margin, indicating its efficiency in converting sales into gross profit.
    • However, its EBITDA and Net Profit Margins are lower than its peers, suggesting potential challenges in managing operating expenses or other factors impacting profitability.
    • BSX's efficiency in generating returns, as measured by ROA, ROE, ROTC, and ROIC, is lower than SYK, indicating potential inefficiencies in generating returns on assets and equity.

  3. Financial Health and Stability:

    • BSX maintains a conservative debt policy, with a lower Total Debt to Total Equity Ratio than its peers and the industry average, contributing to its financial stability.
    • Its liquidity metrics, Current Ratio and Quick Ratio, are lower than the industry average, suggesting potential challenges in meeting short-term obligations.
    • Overall, BSX's financial health is solid, but it faces challenges in achieving consistent profitability and maximizing returns on its assets and equity.

  4. Valuation and Market Perception:

    • BSX's valuation metrics, including EV/Sales, EV/EBITDA, P/E, and P/S, are higher than its peers, suggesting that the market may be placing a higher value on its sales and earnings growth potential.
    • However, its P/B is lower than its peers, indicating that the market may be placing a lower value on its book value.

  5. Cash Flow and Capital Management:

    • BSX generates a higher Free Cash Flow than its peers, suggesting its ability to convert operating cash flow into free cash flow efficiently.
    • This indicates that BSX may be more efficient at managing its capital allocation than its peers.

  6. Growth and Future Prospects:

    • BSX demonstrates strong revenue and earnings growth, particularly in Net Income, Basic Earnings per Share, and Free Cash Flow.
    • However, its growth in free cash flow and profitability metrics is more volatile and may be decelerating, suggesting potential challenges in converting its revenue growth into sustainable profitability.

  7. Potential for Investment:

    • BSX presents a mixed investment proposition. While it exhibits strong revenue and earnings growth, its profitability and efficiency metrics lag behind its larger peers.
    • Investors seeking exposure to the medical device industry with a focus on growth may find BSX attractive, but those seeking higher profitability and efficiency may prefer its larger peers.

  8. Key Risks and Considerations:

    • BSX's lower profitability and efficiency compared to its peers could limit its ability to generate sustainable returns for investors.
    • The volatility in its growth rates, particularly in free cash flow and profitability metrics, suggests potential challenges in achieving consistent performance.
    • While its conservative debt policy contributes to its financial stability, its higher Debt / EBITDA compared to SYK indicates potential risks associated with its debt levels.

  9. Overall Assessment:

    • Boston Scientific Corp. (BSX) is a mid-sized player in the medical device industry with strong revenue and earnings growth. However, its profitability and efficiency metrics lag behind its larger peers, suggesting potential challenges in achieving consistent profitability and maximizing returns on its assets and equity. Despite these challenges, BSX's conservative debt policy and strong cash flow generation contribute to its financial stability. Overall, BSX's financial position is solid, but it faces challenges in achieving consistent profitability and maximizing returns on its assets and equity.